Brief: Evolus Enters Into Licensing Agreement With Symatese To Exclusively Distribute Next-Generation Dermal Fillers In Europe
Dec 20 (Reuters) - Evolus Inc EOLS.O :
* EVOLUS ENTERS INTO LICENSING AGREEMENT WITH SYMATESE TO
EXCLUSIVELY DISTRIBUTE NEXT-GENERATION DERMAL FILLERS IN EUROPE
* EVOLUS INC-EUROPEAN REGULATORY APPROVALS ANTICIPATED IN
SECOND
HALF OF 2024
* EVOLUS INC-CONTINUES TO EXPECT TO BE FULLY FUNDED TO
PROFITABILITY
* EVOLUS INC-INITIAL AGREEMENT IS FOR A TERM OF 15 YEARS,
WITH
AUTOMATIC FIVE-YEAR RENEWAL PROVISIONS
Source text for Eikon: ID:nBw8KsH9ma
Further company coverage: EOLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evolus
See all newsEvolus Inc reports results for the quarter ended June 30 - Earnings Summary
Evolus Q2 revenue rises 21%, lifts 2026 outlook
Brief: Evolus Q2 Product Revenue USD 83.35 Million
Evolus Inc expected to post a loss of 3 cents a share - Earnings Preview
Brief: Evolus Announces Commercial Launch Of Estyme® Injectable Hyaluronic Acid Gels In Europe